|
Main Story
Small is the New Big
Nanotechnology, which has taken the global healthcare industry
by storm, has been showing a great potential for growth on Indian ground too,
discovers Sonal Shukla

In the laboratory micro organisms are used, in order to examine the effects
of nano-particles based materials for living organisms
|
The strength of small is huge, or that is what one ought to
say about the revolution called nanotechnology. And why not! Nanotechnology,
a science which deals with atoms a few nanometres large, has the potential to
make scientific strides across industries. In the IT sector, it holds the key
to creating smaller, more efficient microchips that will make computers faster
and smash existing silicon boundaries. It has ventured into textiles with smart
materials like special surface coatings and cosmetics with efficient durable
action.
However, healthcare is set to be one of the biggest beneficiaries of this nanotech
revolution. In what ways is this technology capable of changing the face of
healthcare? "Tools and techniques devised by nanotechnology will make medical
procedures simpler, quicker, more accurate, and reduce side effects. Diseases
will be diagnosed earlier, and in-treatment monitoring will ensure closed-loop
control of therapeutics," predicts Dr Jayesh Bellare, Professor, Department
of Chemical Engineering, and School of Biosciences and Bioengineering, IIT Mumbai.
According to him, smart drug dosage involves less frequent dosing and better
control of therapeutic indices. Doctors will have a larger arsenal of devices,
tools and techniques at their disposal to customise their treatment to individual
patients. And above all, costs would be contained, because nanotechnology does
not necessarily mean mega-costs. More importantly, aspects of nanotechnology
have the potential to permeate lifestyles so as to raise the wellness index.
This would happen through pure water, low-cost energy, food processing, improved
agricultural practices, safer workplaces and more comfortable homes.
As per the study, 'Nanotechnology in Health Care' from The
Freedonia Group, demand for nanotechnology healthcare products in the US is
projected to increase nearly 50 per cent annually to $6.5 billion in 2009. By
2020, demand for nanotechnology healthcare products is projected to exceed $100
billon.
- Issues of long-term stability of nano-structures
causing concern.
- Technical issues in nano-assembly and molecular
- manufacturing are affecting faster commercialisation.
- Scalability posing a technological challenge
to nano-medicine initiatives.
- Available nano-materials and component
technologies need to be better harnessed for nano-medicine applications.
- Lack of appropriate manufacturing standards
constrains nanotechnology-based applications.
Courtesy: Frost & Sullivan
|
The Small Picture
A nanotechnology application in healthcare is usually expressed as nanomedicine.
"Use of nanotechnology in drug delivery, in vitro diagnostics, smart and
multifunctional biomaterials, imaging and active implants together come under
the umbrella of nanomedicine," says Dr Professor Amarnath Maitra, Department
of Chemistry, University of Delhi and Visiting Scientist, Department of Pathology,
Johns Hopkins Medical Institute, Baltimore, USA.
Nanomedicine may be defined as the monitoring, repair, construction and control
of human biological systems at the molecular level, using engineered nanodevices
and nanostructures. Nanotech in healthcare has invaded areas like drug delivery
systems, pharmaceuticals, biocompatible materials, micro-engineered devices,
improved cardiac catheters and stents. Some examples include nanotechnology-
based synthetic bone for maxillofacial applications, for treating fractures,
and as a scaffold for tissue engineering and differentiation of stem cells,
nanoparticles for pulmonary and ocular delivery, and microengineered transcatheteral
devices for minimally invasive cardiac surgery.
According to Dr Bellare, however, the potential impact is
large, inclusive of artificial organs, tissue engineering, diagnostics of various
sorts (at home, bed-side, ambulatory) battlefield, and outer space. "The
impact will be felt on virtually every facet of healthcare, from pre-birth to
post death," says Bellare.
| The most common method of restoring vision in a corneal
blind individual is cadaveric corneal transplantation, where the healthy
corneal tissue of a donor replaces the damaged cornea of the patient. While
corneal transplant restores vision in cases with localised disorders of
the cornea, albeit with the risk of rejection, it does not suffice in those
with stem cell damage.
A recent advancement is stem cell transplantation,
in which the damaged stem cells are replaced with stem cells from the
other eye of the patient or from a donor. It offers excellent results
when transplanted from the normal opposite eye. However, cadaveric stem
cell transplantation entails long-term immunosuppression with a high risk
of rejection and infection.
Keratoprosthesis (plastic cornea or an artificial
cornea) is the last resort to restore vision in severely damaged eyes
with ocular surface disorders. These act as a foreign body when placed
in the eye with the risk of extrusion and also infection. This necessitates
a carrier for the artificial cornea that would reduce the incidence of
complications encountered with the other types of keratoprostheses. An
ideal carrier was sought for in the tooth which being biological and autologous
(from one's own self) has a long-term retention rate. OOKP is thus a ray
of hope for people who have lost their eyesight due to chemical accidents
and allergic reactions like Stevens Johnson Syndrome.
|
Nano Drug Delivery
Nanotechnology analysts predict that nanotechnology-enabled drug delivery systems
will generate over $1.7 billion (US) in 2009 and over $4.8 billion in 2012.
The global drug delivery products and services market is projected to surpass
US$67 billion in 2009.
Nanotechnology can be incorporated in a wide range of oral dosage presentations
including: tablets (including immediate-release film coated, modified release,
orally disintegrating tablets), capsules (including immediate-release, modified-release),
liquid dispersions and powders. "Apart from offering a solution to solubility
problems, nanobiotechnology provides intracellular delivery possibilities,"
says Shukla. Skin penetration is improved in transdermal drug delivery. A particularly
effective application is non-viral gene therapy vectors. Nanotechnology has
the potential to provide controlled release devices with autonomous operation
guided by needs. "Applications of nanotechnologies in medicine are especially
promising, and areas such as disease diagnosis, drug delivery targeted at specific
sites in the body and molecular imaging are being intensively investigated and
some products are undergoing clinical trials," says Dr Sanjeeb Sahoo, Nanomedicine
Laboratory, Institute of Life Sciences, Bhubaneswar. In therapeutic process,
nanotechnology has two specific roles: (i) entry of drug into the cell by endocytosis
only using nanoparticles as carriers and (ii) targeted delivery of drug to the
desired tissue or cell so as to minimise side effects.
Targeted Impact
"Nanotechnology
research involves low investment and the return is
enormous"
- Dr Prof Amarnath Maitra
Visiting Scientist
Department of Pathology, Johns Hopkins Medical Institute
Baltimore
|
"Drug
delivery targeted at specific sites in the body and molecular imaging are
being intensively investigated"
- Dr Sanjeeb Sahoo
Nanomedicine Laboratory
Institute of Life Sciences Bhubaneswar
|
"The
impact will be felt on virtually every facet of healthcare, from pre-birth
to post death"
- Dr Jayesh Bellare
Professor Department of Chemical Engineering, and School of Biosciences
and Bioengineering
IIT, Mumbai
|
Nanotechnology can drastically reduce drug dosages and side
effects. When drug molecules are administered into the body particularly in
the systemic circulation, they extravagate to all parts of the body by diffusion
and move freely in and out of the cell. These small drug molecules have unrestricted
access to diseased as well as normal tissues in the body. When a certain amount
of drug is administered, only a very small and insignificant amount goes to
the diseased tissues while major part goes to non-diseased sites in the body
causing toxic side effects. "The best example is the use of an anticancer
drug in chemotherapy which has access to all parts of the body killing not only
cancer cells but also normal cells," explains Dr Maitra.
When the same drug molecule is wrapped in nanoparticles,
it cannot diffuse inside the cells but permeates through endocytosis. This is
one-way traffic. The drug-loaded nanoparticles are usually carried by the endosomes
to the lysosomes and are degraded by the enzymatic processso the free
drug comes out and manifests its therapeutic action. Moreover, the nanoparticles
are tailor-made chemical entities and so surface modification of these nanoparticles
with suitable molecules is possible. These molecules help recognition of these
particles by the cell surface. As a result, one can have targeted delivery of
drug to the desired sites in the body (say diseased tissues) and thereby reduce
the side reaction.
If we assume that one drug molecule can kill one cell and
1000 is the molecular weight of drug molecule, then 1013 drug molecules can
kill all the cells in the body which comes out to be about 100ng of drug. Dr
Maitra cites an example of treatment of throat infection by antibiotics. The
patient takes a couple of hundred milligrams of antibiotics. "If we consider
that one antibiotic molecule can kill one bacterium in the body, then we need
only few nanograms or even less of the drug. If the antibiotic is loaded in
engineered nanoparticles which can be orally administered and can be targeted
to the throat bacteria, one can have the same or better therapeutic effect with
a few nanograms of drug with significantly reduced side effects," he explains.
This is due to the combined effect of endocytosis and targeting. This is how
nanotechnology can change the face of healthcare sector, eliminating the wastage
of drug by targeted delivery and minimisation of side effect. In the near future,
the most important clinical applications of nanotechnology are likely to be
in pharmaceutical development.
Says Dr Sahoo, "There are already an astonishing number of emerging applications.
These applications either take advantage of the unique properties of nanoparticles
as drugs or components of drugs per se or are designed for new approaches to
controlled release, drug targeting and salvage of drug with low bioavailability."
For example, nanoscale polymer capsules can be designed to break down and release
drugs at controlled rates and to allow differential release in certain environments,
such as an acid milieu, to promote uptake in tumours versus normal tissues.
"Substantial research is now devised for creating novel polymers and exploring
specific drug-polymer combinations," he adds.
Nanotechnology is opening new therapeutic opportunities for
many agents that cannot be used effectively as conventional oral formulations
because of their poor bioavailability. "In some cases, reformulation of
a drug with smaller particle size may improve oral bioavailability," says
Dr Sahoo.
Nano molecular diagnostics: Some of the earliest applications
of nanotechnology in pharmaceuticals are in molecular diagnostics. Because of
the small dimensions, most of the applications of nanobiotechnology in molecular
diagnostics fall under the broad category of biochips/microarrays. Biochips
constructed with microelectromechanical systems are on a micron scale and related
to micromanipulation, whereas nanotechnology-based chips are on a nanoscale
and related to nanomanipulation. "Even though microarray/biochip methods
making use of the detection of specific biomolecular interactions are now an
indispensable tool for molecular diagnostics, there are some limitations,"
Dr Sahoo concedes. DNA microarrays and enzyme-linked immunosorbent assays rely
on the labelling of samples with a fluorescent or radioactive tag, a highly
sensitive procedure that is time-consuming and expensive.
Nanotechnology is being applied to overcome some of the limitations
of biochip technology. "Nanotechnology on a chip is one more dimension
of microfluidic/lab-on-a-chip technology. Biological tests measuring the presence
or activity of selected substances become quicker, more sensitive and more flexible
when certain nanoscale particles are put to work as tags or labels," explains
Dr Sahoo. According to experts, nanotechnology on a chip is a new paradigm for
total chemical analysis systems. The ability to make chemical and biological
information much cheaper and easier to obtain is expected to fundamentally change
healthcare, food safety and law enforcement. "Numerous nanodevices and
nanosystems for sequencing single molecules of DNA are feasible. Various nanodiagnostics
that have been reviewed will improve the sensitivity and extend the present
limits of molecular diagnostics," opines Shivani Shukla, Programme Manager
Healthcare Practice, Frost & Sullivan.
| Sankara Nethralaya claims to have pioneered the surgery
in India in March 2003. The first few surgeries were done under the personal
guidance of Prof Gian Carlo Falcinelli himself here. Dr G Sitalakshmi, who
was trained by Prof Falcinelli, later took charge of OOKP in the hospital.
After her sudden demise, Dr Iyer, who was working with her in the team from
early days, heads the team.
Dr Rao, who was fortunate to study the technique
from Prof Falcinelli, was part of the team that conducted OOKP for the
first time in India. Today, Dr Rao performs OOKP in Rajan Eye Care Hospital,
Chennai along with Dr Sujatha Mohan, Associate Medical Director of the
Hospital. Rajan Eye Care is performing OOKP since 2006. They were successful
in giving vision to seven patients through this procedure so far.
Bombay Hospital and Research Centre, Mumbai, too
successfully conducted the OOKP procedure recently. Dr Nankani and her
team carried out the procedure a few months ago. "I followed steps
similar to Prof Falcinelli without undergoing direct training from him,"
said Dr Nankani.
Apart from Italy and India, OOKP is performed in
countries like Germany, Austria, Hong Kong and Singapore.
|
Nano in imaging: According to experts, nanotechnology
has displayed the potential to transform the field of medicine, because it offers
novel opportunities for sensing clinically relevant markers, molecular disease
imaging, and tools for therapeutic interventions. "Nanotechnology already
affords the possibility of intracellular imaging through attachment of Quantum
Dots (QDs) or synthetic chromophores to selected molecules. Proteins, for example,
or by the incorporation of naturally occurring fluorescent proteins that, with
optical techniques such as confocal microscopy and correlation imaging, allow
intracellular biochemical processes to be investigated directly," explains
Dr Sahoo. QDs are semiconductor nanocrystals with unique optical and electrical
properties. Among others, one of their most valuable properties is their fluorescence
spectrum, which renders them optimal fluorophores for biomedical imaging.
Nano gene therapy: Gene therapy is a recently introduced
method for treatment or prevention of genetic disorders by correcting defective
genes responsible for disease development based on the delivery of repaired
genes or the replacement of the incorrect ones. "The most common approach
for correcting faulty genes is insertion of a normal gene into a non-specific
location within the genome to replace a non-functional gene," explains
Dr Sahoo.
Nano cardiac therapy: Today, nanotechnology offers
a broad platform in the field of cardiovascular science at the cellular level.
"Nanotechnology-based tools can be effectively used to treat cardiovascular
diseases. These tools can be used in the areas of diagnosis, imaging and tissue
engineering," says Dr Sahoo. Miniaturised nanoscale sensors like QDs, nanocrystals,
and nanobarcodes can sense and monitor biological signals such as the release
of proteins or antibodies in response to cardiac or inflammatory events.
Nanotechnology can also help in revealing the mechanisms involved in various
cardiac diseases.
Nanotechnology can also be an effective answer to curb restenosis the
obstruction of an artery after interventional procedures such as balloon angioplasty
and a major problem with 30-50 per cent of patients developing reocclusion,
with 20 per cent requiring additional intervention. "Although different
therapeutic strategies have been investigated for the inhibition of restenosis,
the main drug therapy approach is targeted toward inhibiting the proliferation
and migration of smooth muscle cells. Systematic administration of therapeutic
agents has been ineffective in preventing restenosis," states Dr Sahoo.
According to him, researchers have a great hope that nanotechnology-based localised
drug therapy using sustained-release drug delivery systems could be more effective,
because it can provide higher and prolonged drug levels in the target tissues
without causing systemic toxicity.
Nano dentistry: Nanodentistry will bring the maintenance
of near-perfect oral health through the use of nanomaterials, biotechnology
and nanorobotics. "In the years to come, it will be possible through nanodentistry
to induce local anaesthesia with the help of active analgesic dental nanorobotic
particles. Apart from this, nanodental techniques for major tooth repair may
also evolve," Dr Sahoo forecasts.
Moreover, nanodentistry could also play a vital role in natural tooth maintenance
wherein appearance and durability of teeth may be improved by replacing upper
enamel layers with covalently bonded artificial materials such as sapphire or
diamond, which have 20 to 100 times the hardness and strength of natural enamel.
Nano orthopaedics: Muscu-loskeletal disorders have
become a major concern today, given an aging population and an increased occurrence
of sports-related injuries. Current treatment modalities include orthopaedic
implants used for internal fixing of fractured bones. These, however, have been
bogged down by the problem of implant failures. Says Dr Sahoo, "Nanotechnology
can provide an alternative platform with higher mechanical strength, enhanced
bioavailability, and resorbability to improve the quality of life of patients
who suffer from debilitating bone fractures."
Indian Nano
The Indian scenario for nanotechnology research, while still nascent, has been
showing an increased level of interest. Indian nanotechnology work impinging
on healthcare is in the field of nanomaterials and nanocomposites, nanoparticles,
imaging technology for high-resolution microscopy. Government funding agencies
particularly the Department of Science and Technology, and the Department of
Biotechnology are funding research as well as private-public partnership projects
in this area. "Some doctors interested in research and working in hospitals
are actively collaborating with the IITs for innovation. Some forward-thinking
industries are also working towards this," says Dr Bellare. Some active
institutions in nanotechnology research arena include AIIMS, Tata Memorial Centre,
Nanavati Hospital, Glenmark and Nicholas Piramal. According to some, research
in nanotechnology on Indian soil still has miles to go. Says Utkarsh Palnitkar,
Partner, Ernst &Young, "Oncology is the only therapeutic area wherein
nanotech is being applied in India, although the potential is immense since
it can be applied for any targeted therapy."
"Nanotechnology in healthcare should be considered as one of the important
areas of research in India because it involves low investment and the return
is enormous so far as the public benefit is concerned," opines Dr Maitra.
Future in Devices
According to Dr Maitra, the Indian pharma industry is interested in quick money
and therefore they are more involved in generic drugs and exporting them. In
2007 alone, $18 million of generic drugs have been exported. On the other hand,
academia are only interested in mediocre basic research and publications.
Although the share of nanotechnology in the drug delivery market is growing
by leaps and bounds, it is shadowed by some concerns. "It is widely observed
that while big pharma companies are 'flat footed' in their initiative about
nanotechnology, medical device companies are more aggressive in pursuing nano
technological strategies," says Shukla.
healthcare@expressindia.com
|